Investors & Media

Corporate Profile

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has five programs in active clinical development.

Corporate Presentation

NGM Bio Corporate Presentation May 2023

Explorer Series 1: NGM Bio’s Discovery Engine

Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs

Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate

Explorer Series 4: NGM621

CATALINA Topline Results Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News & Events

News Releases

May 25, 2023

NGM Bio to Participate in Upcoming Investor Conferences

May 8, 2023

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

May 4, 2023

NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

Contact Information

investor relations

media relations